GlassScriptPhysician profile
Matthew Bryan Greene
NPI 1457616898
$1,397.73
in general payments reported to CMS, 2019-2025
13 companies · $539 in 2025
The $539 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $81.16 · 2021: $96.71 · 2022: $61.65 · 2023: $124 · 2024: $337 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.14 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.95 | 2022-2025 | |
| Allergan, INC. | $295.69 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $155.53 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $153.84 | 2021-2024 | Total30, Dailies |
| Dompe US, INC. | $100.11 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $65.67 | 2022-2025 | Vyzulta, Miebo |
| Glaukos Corporation | $47.52 | 2024 | Radius |
| Sun Pharmaceutical Industries INC. | $40.85 | 2024-2025 | |
| Thea Pharma INC. | $35.36 | 2023-2025 | Iyuzeh |
| Ani Pharmaceuticals, INC. | $23.48 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $19.39 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.88 | 2019 | |
| Oyster Point Pharma, INC. | $15.46 | 2025 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.